Specimen · Stack · 2 components
Sermorelin + Ipamorelin
Also called: Sermorelin/Ipamorelin
AnecdotalUnclear⚠ none in humans
A growth-hormone-secretagogue combination pairing sermorelin (a short-acting GHRH analog) with ipamorelin, often framed as a gentler alternative to the CJC-1295 stack.
What's in the Sermorelin + Ipamorelin stack
Why people combine them
Like the CJC-1295 stack, this pairs two different GH-release pathways: sermorelin is a GHRH analog (the natural GRF 1-29 sequence) and ipamorelin is a selective ghrelin/GHSR secretagogue. Sermorelin is shorter-acting than CJC-1295, so people choose this version when they want a more physiologic, pulsatile GH signal rather than a long, sustained one. The combined effect is still community practice, not a tested protocol.
Sermorelin + ipamorelin is the gentler sibling of the CJC-1295 stack. It uses the same two-pathway idea — a GHRH analog (sermorelin) plus a selective secretagogue (ipamorelin) — but sermorelin is shorter-acting, so the GH signal is more of a natural pulse than a sustained plateau. People who want a more physiologic approach often pick this version.
Sermorelin has a longer regulatory and clinical history than most compounds in this space, which is a point in its favor, but the combination as used today still hasn’t been through controlled human outcome trials — so the stack itself is graded anecdotal. The compatibility note below reflects that a GHRH analog plus a secretagogue is the pairing most commonly co-administered.
What the evidence says
As a combination, the Sermorelin + Ipamorelin stack has no controlled human trials behind it — the components are studied mostly on their own, and running them together is community practice, not a tested protocol. We grade the stack itself anecdotal.
Can these share a syringe?
Whether the components can be drawn into one injection is a separate, physical question from whether the stack is a good idea. Here's what's known for these pairs — and ourmixing-compatibility reference covers every pairing, with "insufficient data" wherever the research is genuinely silent.
Sermorelin + Ipamorelin
Commonly combined in one syringe
A GHRH analog plus a GHRP-class secretagogue is the pairing most commonly co-administered; community practice routinely draws them together. Common practice, not an endorsement — see the mixing-compatibility tool.
Safety & regulatory notes
Sermorelin has a longer clinical history than most research peptides (it was once an approved diagnostic/therapeutic agent), but the sermorelin + ipamorelin combination as run today has no controlled human outcome data. As with any GH-raising approach, water retention, joint discomfort and insulin-sensitivity effects are the usual considerations.
Sermorelin has a regulatory history but the compounded/research forms and ipamorelin are used research-off-label or research-use-only here; growth-hormone secretagogues are prohibited in sport under the WADA list. Re-verify status after the July 2026 FDA advisory-committee outcome.
Preparing the components
Each component is a lyophilized powder that has to be reconstituted before use. Ourreconstitution & dosing calculatorturns vial size, water, and target dose into the exact insulin-syringe units to draw, and the cost-per-dose calculator shows what a full cycle runs.